- Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - GAINESVILLE, Fla. , and CAMBRIDGE, Mass.
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2H 2020 - - Company on track for End of Phase 2 meeting in Q2 2020 - - Company sees minimal COVID-19 impact to date - - Company to host conference call and webcast today at 8:00am ET - GAINESVILLE, Fla.
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , May 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
Enrollment ongoing in pediatric dose groups Interim data of all adult dose groups expected in 2H of 2020 GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
–Encouraging preliminary signs of biologic activity and a favorable safety profile are outcomes that are clinically relevant to patients – Enrollment ongoing in additional dose groups, which will include pediatric patients; interim data from these additional dose groups expected in 2H of 2020 –
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
Management and External Thought Leaders to Discuss Data from XLRP and ACHM Phase 1/2 Clinical Trials Webcast Scheduled from 7:30 am – 12:00 pm ET GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
